Floatz logo

IPN 60090

Chondrosarcoma

M.D. Anderson Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Chondrosarcoma cohort.

Asset / SponsorPhaseRating
ag-120
Memorial Sloan Kettering Cancer Center
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
Eli Lilly and Company
Phase 1/2CCC
Angiotensin-(1-7)
Wake Forest University Health Sciences
Phase 2CCC
Azacitidine
IGM Biosciences, Inc.
Phase 1/2CCC
Adapt-001
EpicentRx, Inc.
Phase 2CCC

View all 24 →

Same molecule, other indications

IPN 60090 is also rated in:

head and neck squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
endometrial carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
ovarian clear cell adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →